MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

Legend Biotech Corp ADR

Open

SectorGezondheidszorg

31.85 -1.67

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.53

Max

32.36

Belangrijke statistieken

By Trading Economics

Inkomsten

-26M

-125M

Verkoop

61M

256M

Winstmarge

-48.758

Werknemers

2,800

EBITDA

-25M

-114M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+135.92% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-530M

6.2B

Vorige openingsprijs

33.52

Vorige sluitingsprijs

31.85

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Legend Biotech Corp ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 aug 2025, 11:06 UTC

Winsten

Legend Biotech 2Q Loss/Shr 34c >LEGN

11 aug 2025, 11:06 UTC

Winsten

Legend Biotech 2Q Loss $125.4M >LEGN

11 aug 2025, 11:00 UTC

Winsten

Legend Biotech 2Q Rev $255.1M >LEGN

13 mei 2025, 11:01 UTC

Winsten

Legend Biotech 1Q Loss/Shr 27c >LEGN

13 mei 2025, 11:00 UTC

Winsten

Legend Biotech 1Q Rev $195.1M >LEGN

11 mrt 2025, 11:09 UTC

Winsten

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11 mrt 2025, 11:08 UTC

Winsten

Legend Biotech 4Q EPS 7c >LEGN

11 mrt 2025, 11:00 UTC

Winsten

Legend Biotech 4Q Rev $186.5M >LEGN

12 nov 2024, 12:06 UTC

Winsten

Legend Biotech 3Q Loss/Shr 34c >LEGN

12 nov 2024, 12:05 UTC

Winsten

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12 nov 2024, 12:00 UTC

Winsten

Legend Biotech 3Q Rev $160.2M >LEGN

Peer Vergelijking

Prijswijziging

Legend Biotech Corp ADR Prognose

Koersdoel

By TipRanks

135.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 77.05 USD  135.92%

Hoogste 94 USD

Laagste 62 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Legend Biotech Corp ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technische score

By Trading Central

30.5 / 33.91Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
help-icon Live chat